Kura Oncology Announces Positive Phase 2 Trial of Tipifarnib in Peripheral T-Cell Lymphoma
June 14, 2019 07:00 ET
|
Kura Oncology, Inc.
– Primary endpoint achieved with 45% and 42% ORR in AITL and CXCL12+ AITL/PTCL-NOS expansion cohorts – – PTCL patients with tumors characterized by high CXCL12/CXCR4 expression ratio experienced an...
BeiGene Announces Clinical Results from Three Posters on Zanubrutinib Presented at the 24th Congress of European Hematology Association (EHA)
June 14, 2019 02:30 ET
|
BeiGene, LTD.
First Preliminary Data from Exploratory MYD88WT Patient Cohort in Phase 3 Trial in Waldenström’s Macroglobulinemia (WM); Updated Phase 1/2 WM Data; and Pooled Safety Data Analysis on Zanubrutinib in...
BeiGene Announces Updated Results from a Pivotal Phase 2 Study of Tislelizumab in Chinese Patients with Relapsed or Refractory Classical Hodgkin Lymphoma at the 24th Congress of the European Hematology Association (EHA)
June 14, 2019 02:30 ET
|
BeiGene, LTD.
CAMBRIDGE, Mass. and BEIJING, China, June 14, 2019 (GLOBE NEWSWIRE) -- BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160), a commercial-stage biopharmaceutical company focused on developing and...
Geron to Webcast KOL Event on June 25, 2019
June 10, 2019 16:45 ET
|
Geron Corporation
MENLO PARK, Calif., June 10, 2019 (GLOBE NEWSWIRE) -- Geron Corporation (Nasdaq: GERN) today announced that the Company will webcast an event on June 25, 2019, featuring key opinion leaders (KOLs)...
Onconova Therapeutics Announces Presentations at the 24th Congress of the European Hematology Association
June 10, 2019 07:30 ET
|
Onconova Therapeutics, Inc.
NEWTOWN, Pa., June 10, 2019 (GLOBE NEWSWIRE) -- Onconova Therapeutics, Inc. (NASDAQ:ONTX), a Phase 3-stage biopharmaceutical company focused on discovering and developing novel products to treat...
Aptose to Present New Preclinical Data for CG-806 at the 24th Congress of The European Hematology Association
May 16, 2019 10:02 ET
|
Aptose Biosciences, Inc.
SAN DIEGO and TORONTO, May 16, 2019 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. (“Aptose” or the “Company”) (NASDAQ: APTO, TSX: APS), a clinical-stage company developing highly differentiated...
Geron Announces Two Presentations on Imetelstat at Upcoming European Hematology Association Annual Congress
May 16, 2019 09:05 ET
|
Geron Corporation
MENLO PARK, Calif., May 16, 2019 (GLOBE NEWSWIRE) -- Geron Corporation (Nasdaq: GERN) today announced that two abstracts containing clinical data and analyses related to imetelstat, the Company’s...
BeiGene Announces Clinical Data on Tislelizumab and Zanubrutinib to be Presented at the 24th Congress of the European Hematology Association
May 16, 2019 09:00 ET
|
BeiGene, LTD.
CAMBRIDGE, Mass. and BEIJING, China, May 16, 2019 (GLOBE NEWSWIRE) -- BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160), a commercial-stage biopharmaceutical company focused on developing and...
Geron Reports Imetelstat Oral Presentation at European Hematology Association Congress
June 18, 2018 06:45 ET
|
Geron Corporation
MENLO PARK, Calif., June 18, 2018 (GLOBE NEWSWIRE) -- Geron Corporation (Nasdaq:GERN) today announced the oral presentation of updated data from the ongoing original Part 1 of IMerge, the Phase 2/3...
Nohla Announces Presentation of Dilanubicel (NLA101) Data at EHA Annual Meeting Showcasing Excellent Long-term Survival Outcomes
June 15, 2018 11:30 ET
|
Nohla Therapeutics
SEATTLE, June 15, 2018 (GLOBE NEWSWIRE) -- Nohla Therapeutics, a leading developer of universal, off-the-shelf cell therapies for patients with hematologic malignancies and other critical diseases,...